Table 1 Likelihood χ2 ratios by test and cohort.

From: Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study

 

ER+/HER2− (N = 3284)

Trinary classification

Binary classification

 

df

LRχ2

p-value

df

LRχ2

p-value

Univariate models

 Oncotype

2

118.0

<0.0001

1

109.87

<0.0001

 Prosigna

2

146.9

<0.0001

1

127.31

<0.0001

 Mammaprint

1

119.5

<0.0001

1

119.45

<0.0001

Bivariate models

      

 Oncotype + Prosigna

4

177.9

<0.0001

2

164.47

<0.0001

 Oncotype + Mammaprint

3

145.7

<0.0001

2

143.34

<0.0001

 Prosigna + Mammaprint

3

168.8

<0.0001

2

155.11

<0.0001

Bivariate vs. univariate

 Oncotype + Prosigna vs. Oncotype

2

59.97

<0.0001

1

54.60

<0.0001

 Oncotype + Mammaprint vs. Oncotype

1

27.78

<0.0001

1

33.48

<0.0001

 Prosigna + Oncotype vs. Prosigna

2

31.02

<0.0001

1

37.16

<0.0001

 Prosigna + Mammaprint vs. Prosigna

1

21.89

<0.0001

1

27.80

<0.0001

 MammaPrint + Oncotype vs. Mammaprint

2

26.28

<0.0001

1

23.89

<0.0001

 Mammaprint + Prosigna vs. Mammaprint

2

49.34

<0.0001

1

35.65

<0.0001

  1. LRχ2 = likelihood ratio chi-squared value, all models run exiting at 10 years. Likelihood χ2 ratios(LRχ2) for univariate(single test) or bivariate(two tests in sequence) derived using 10-year distant metastasis free survival as end point, ER+/HER2+ve cases = all ER+ve/HER2−ve cases (irrespective of nodal status and chemotherapy), ΔLRχ2 = change in Likelihood χ2 ratio when two tests are used sequentially. Trinary classification: results using results from Oncotype-Dx trained and Prosigna-trained tests categorized as low, intermediate, and high risk, binary classification: results using dichotomous results for all tests, see text for cut-points, ΔLRχ2 = change in LRχ2 for comparison of 2 tests versus a single test.
Back to article page